IL2 and melanoma: In a xenograft melanoma model, it has been demonstrated that the combination of L19-IL-2 with anti-SDC1 OC-46F2 mAb resulted in the complete inhibition of melanoma growth for up to three months after tumor injection in 71% of the treated mice [96].